TipRanks
Advertisement
Advertisement

GB:AZN Stock Latest News

AstraZeneca upgraded to Buy from Sell at Nordea
The FlyAstraZeneca upgraded to Buy from Sell at Nordea
9h ago
AZN
AstraZeneca announces ALXN1850 did not achieve statistical significance
PremiumThe Fly
AstraZeneca announces ALXN1850 did not achieve statistical significance
2d ago
AZN
NIH makes big bet on public-private partnership over cancer vaccines, NYT says
PremiumThe Fly
NIH makes big bet on public-private partnership over cancer vaccines, NYT says
4d ago
AZN
JNJ
Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion
PremiumThe Fly
Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion
5d ago
GH
AZN
AstraZeneca’s Kazakhstan Breast Cancer Study: Real‑World Data With Quiet but Important Signals for AZN
PremiumCompany Announcements
AstraZeneca’s Kazakhstan Breast Cancer Study: Real‑World Data With Quiet but Important Signals for AZN
5d ago
AZN
Myriad, Sophia advance prostate cancer-specific genomic instability score tech
PremiumThe FlyMyriad, Sophia advance prostate cancer-specific genomic instability score tech
5d ago
AZN
MYGN
Sophia Genetics and Myriad Genetics collaborate in prostate cancer score tech
Premium
The Fly
Sophia Genetics and Myriad Genetics collaborate in prostate cancer score tech
5d ago
AZN
MYGN
AstraZeneca price target raised to 18,600 GBp from 17,800 GBp at Citi
Premium
The Fly
AstraZeneca price target raised to 18,600 GBp from 17,800 GBp at Citi
7d ago
AZN
AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus
PremiumCompany Announcements
AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus
7d ago
AZN
AstraZeneca opens R&D center in Cambridge, Massachusetts
PremiumThe Fly
AstraZeneca opens R&D center in Cambridge, Massachusetts
8d ago
AZN
AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target
PremiumRatings
AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target
8d ago
AZN
AstraZeneca completes $2B equity investment in Summit Therapeutics
PremiumThe Fly
AstraZeneca completes $2B equity investment in Summit Therapeutics
8d ago
AZN
SMMT
AstraZeneca invests $2bn in Summit to accelerate bispecific and ADC cancer portfolio
PremiumCompany AnnouncementsAstraZeneca invests $2bn in Summit to accelerate bispecific and ADC cancer portfolio
8d ago
AZN
Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo
Premium
The Fly
Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo
11d ago
AZN
SMMT
AstraZeneca, Daiichi Sankyo and Summit expand ADC–immunotherapy push with Datroway–ivonescimab trials
Premium
Company Announcements
AstraZeneca, Daiichi Sankyo and Summit expand ADC–immunotherapy push with Datroway–ivonescimab trials
11d ago
AZN
AstraZeneca Adds Employee Scheme Shares to London Listing
PremiumCompany Announcements
AstraZeneca Adds Employee Scheme Shares to London Listing
12d ago
AZN
AstraZeneca Confirms Total Voting Rights and Share Capital Structure
PremiumCompany Announcements
AstraZeneca Confirms Total Voting Rights and Share Capital Structure
12d ago
AZN
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
PremiumRatings
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
14d ago
AZN
Morning Movers: Summit Therapeutics jumps after AstraZeneca investment
PremiumThe Fly
Morning Movers: Summit Therapeutics jumps after AstraZeneca investment
14d ago
MU
AIR
AstraZeneca’s Oncology Strategy and Summit Deal Reinforce Growth Outlook; Buy Rating and $178 Price Target Reiterated
PremiumRatingsAstraZeneca’s Oncology Strategy and Summit Deal Reinforce Growth Outlook; Buy Rating and $178 Price Target Reiterated
14d ago
AZN
AstraZeneca’s Summit Partnership Bolsters Oncology Strategy; Buy Rating Reiterated with Unchanged 16,500 GBp Price Target
Premium
Ratings
AstraZeneca’s Summit Partnership Bolsters Oncology Strategy; Buy Rating Reiterated with Unchanged 16,500 GBp Price Target
14d ago
AZN
Summit Therapeutics price target raised to $43 from $40 at Citi
Premium
The Fly
Summit Therapeutics price target raised to $43 from $40 at Citi
14d ago
AZN
SMMT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >